Through its Precision Care Companion, McKesson wants to help oncologists bring personalized medicine to their patients ...

Leukemia patients who enroll in LLS's PedAL screening trial and are found to have certain alterations will be directed to receive ziftomenib in a Phase I study.

If the European Commission approves this treatment, it'll be the first HER2-targeted agent for HER2-positive biliary tract cancer available to patients in the EU.

Mosaic gained ASTX029, an ERK1/2 inhibitor, and ASTX295, an MDM2 antagonist, in the deal, which it hopes to advance in biomarker-defined indications.